Redefining Glycan Control With In Vitro Glycoengineering

Glycoprotein-based therapies face a critical and unpredictable challenge in achieving a consistent glycan profile, a key issue that can lead to safety risks and costly development delays. Conventional methods rely on manipulating the host cell's machinery, which often results in inconsistent results.

In Vitro Glycoengineering (IVGE) represents an alternative approach that offers true molecular control. By moving glycan modification to a precise, enzymatic step after the protein is produced, IVGE ensures lot-to-lot consistency, improves efficacy and pharmacokinetics, and accelerates development timelines.

Now more accessible due to a collaboration that provides the necessary reagents, IVGE is emerging as a critical tool for revolutionizing the quality and safety of next-generation biotherapeutics. Download the full article to learn more about this transformative solution.